TrialSpark, a tech-driven drug developer with its portfolio of clinical-stage drug assets, is rebranding to Formation Bio. The new name is a reflection of the company's evolution and its progress toward building a pharma company designed to achieve its founding mission: to bring new treatments to patients faster and more efficiently.
Despite sweeping advancements in biotechnology, bringing a new drug to market remains a decade-long, billion-dollar endeavor. While AI makes drug discovery more efficient than ever, the biopharma industry can only develop some of the drugs it discovers. Many promising drugs that could help patients don't get developed, as the high costs of clinical trials limit the number of pipeline assets companies can advance.
Formation Bio in-licenses or acquires promising clinical-stage drug assets from biotech and pharma companies that can't develop the assets themselves for financial or strategic reasons. The company leverages its proprietary tech-driven development engine to progress its pipeline faster and more efficiently than industry norms, ultimately striving to create value for its partners and increase the throughput for patients. Their model, which brings together technical depth and pharma acumen, lays the foundation for the future pharma company, which will be characterized by speed, operational excellence, and first principles thinking.
TrialSpark was founded in 2016 to create this generation's tech-driven pharma company differentiated by radically more efficient clinical trials. Before acquiring its pipeline, the company spent its early years focused on sparking innovation within all aspects of clinical trials and drug development, building clinical trial technology tools for drug developers, including software and platforms for digital patient recruitment and site management. With this rebrand, Formation Bio marks the next phase of its journey to create this generation's pharma company, by building upon its early success in acquiring and developing a portfolio of assets across numerous therapeutic areas.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!